The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.83% and ...

Discover the first FDA-approved weight loss medication for obstructive sleep apnea, Zepbound by Eli Lilly. Learn how it can reduce apnea events and CPAP market.

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

The statistics continue to be alarming, with no indication that the global rise in obesity is slowing. The real question ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Find insight on Novo Nordisk and more in the latest Market Talks covering Health Care.

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...